Evaluation of Direct-Acting Antiviral (DAA) Regimens on hepatitis C.

Evaluation of the Effectiveness of Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C: A Multicenter and Follow-up Analysis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20081110001444N7

Enrollment

Registered

2022-02-24

Start date

2021-12-30

Completion date

Unknown

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C. Chronic viral hepatitis C

Interventions

Intervention group: In this study, therapeutic DAA regimen prescribed for the treatment of the patients with GT3 virus was SOF 400 mg + DCV 60 mg.For the other GT cases, it was SOF 400 mg + LDV 90. Ac

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Adults (= 18 years) regardless of their previous treatment or stage of liver fibrosis

Exclusion criteria

Exclusion criteria: The patients who took drugs including carbamazepine, phenytoin, rifampin, phenobarbital, antacids and rosuvastatin had a history of taking amiodarone in the past three months those with severe renal insufficiency pregnant women patients with no high life expectancy due to other diseases

Design outcomes

Primary

Measure	Time frame
Sustained virological response. Timepoint: After 12 weeks. Method of measurement: Polymerase Chain Reaction (PCR).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohsen Akhondi Meybodi

Yazd University of Medical Sciences

akhondei@yahoo.com+98 35 3822 4000

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026